JP4533898B2 - トリアゾール誘導体およびその代謝関連障害の処置方法 - Google Patents

トリアゾール誘導体およびその代謝関連障害の処置方法 Download PDF

Info

Publication number
JP4533898B2
JP4533898B2 JP2006536942A JP2006536942A JP4533898B2 JP 4533898 B2 JP4533898 B2 JP 4533898B2 JP 2006536942 A JP2006536942 A JP 2006536942A JP 2006536942 A JP2006536942 A JP 2006536942A JP 4533898 B2 JP4533898 B2 JP 4533898B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
cyclopentapyrazole
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006536942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509181A (ja
JP2007509181A5 (https=
Inventor
グレーム セムプル，
トーマス シュレーダー，
フィリップ ジェイ． スキナー，
スティーブン エル． コレッティー，
タウフィーク ガーバウイ，
ジェイソン イー． イムブリグリオ，
ジャエ−キュー ジュン，
ルイ リャン，
サブヘアカー ラグハバン，
ダービー シュミット，
ジェイムス アール． タタ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2007509181A publication Critical patent/JP2007509181A/ja
Publication of JP2007509181A5 publication Critical patent/JP2007509181A5/ja
Application granted granted Critical
Publication of JP4533898B2 publication Critical patent/JP4533898B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006536942A 2003-10-31 2004-10-29 トリアゾール誘導体およびその代謝関連障害の処置方法 Expired - Fee Related JP4533898B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010053852A Division JP2010163448A (ja) 2003-10-31 2010-03-10 トリアゾール誘導体およびその代謝関連障害の処置方法

Publications (3)

Publication Number Publication Date
JP2007509181A JP2007509181A (ja) 2007-04-12
JP2007509181A5 JP2007509181A5 (https=) 2010-06-17
JP4533898B2 true JP4533898B2 (ja) 2010-09-01

Family

ID=34572875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006536942A Expired - Fee Related JP4533898B2 (ja) 2003-10-31 2004-10-29 トリアゾール誘導体およびその代謝関連障害の処置方法
JP2010053852A Pending JP2010163448A (ja) 2003-10-31 2010-03-10 トリアゾール誘導体およびその代謝関連障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010053852A Pending JP2010163448A (ja) 2003-10-31 2010-03-10 トリアゾール誘導体およびその代謝関連障害の処置方法

Country Status (37)

Country Link
US (2) US8637555B2 (https=)
EP (2) EP1683794A1 (https=)
JP (2) JP4533898B2 (https=)
KR (1) KR100850591B1 (https=)
CN (1) CN1867562B (https=)
AR (1) AR046611A1 (https=)
AT (1) ATE328880T1 (https=)
AU (1) AU2004287861B2 (https=)
BR (1) BRPI0415631A (https=)
CA (1) CA2539985C (https=)
CO (1) CO5690551A2 (https=)
CR (1) CR8270A (https=)
CY (1) CY1105479T1 (https=)
DE (1) DE602004001134T2 (https=)
DK (1) DK1599469T3 (https=)
EA (1) EA011484B1 (https=)
EC (1) ECSP066529A (https=)
ES (1) ES2267077T3 (https=)
GE (1) GEP20094801B (https=)
HR (1) HRP20060286T3 (https=)
IL (1) IL174042A0 (https=)
IS (1) IS2372B (https=)
MA (1) MA28171A1 (https=)
MX (1) MXPA06004556A (https=)
MY (1) MY140410A (https=)
NO (1) NO20062509L (https=)
NZ (1) NZ546285A (https=)
PE (1) PE20050483A1 (https=)
PL (1) PL1599469T3 (https=)
PT (1) PT1599469E (https=)
RS (1) RS20060290A (https=)
SI (1) SI1599469T1 (https=)
TN (1) TNSN06150A1 (https=)
TW (1) TWI258478B (https=)
UA (1) UA86783C2 (https=)
WO (1) WO2005044816A1 (https=)
ZA (2) ZA200603419B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
DE602004022864D1 (de) 2003-11-21 2009-10-08 Arena Pharm Inc 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
CN101076331A (zh) * 2004-11-05 2007-11-21 艾尼纳制药公司 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (en) 2005-04-28 2008-01-16 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles
SI1901731T1 (sl) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN105102457A (zh) 2013-02-21 2015-11-25 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
JP6453216B2 (ja) * 2013-07-23 2019-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
HUP0301493A2 (hu) 2000-03-09 2003-08-28 Ono Pharmaceutical Co., Ltd. Indolszármazékok, eljárás előállításukra és alkalmazásuk
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
PL204958B1 (pl) 2000-06-30 2010-02-26 Glaxo Group Ltd Ditosylany związków chinazolinowych, środek farmaceutyczny i zastosowanie tych związków
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
JP4279561B2 (ja) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
PT1397351E (pt) 2001-06-01 2010-01-04 Hoffmann La Roche Derivados de pirimidina, triazina e pirazina como receptores de glutamato
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
US6884750B2 (en) 2001-06-27 2005-04-26 Rs Tech Corp. Chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst
KR20040044856A (ko) 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
ATE516277T1 (de) 2002-03-19 2011-07-15 Ono Pharmaceutical Co Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (en) * 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2528834A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN101103030B (zh) 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
US20070244107A1 (en) 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
CN101076331A (zh) 2004-11-05 2007-11-21 艾尼纳制药公司 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (en) 2005-04-28 2008-01-16 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles

Also Published As

Publication number Publication date
CA2539985C (en) 2010-02-16
CY1105479T1 (el) 2010-07-28
AR046611A1 (es) 2005-12-14
PT1599469E (pt) 2006-10-31
ECSP066529A (es) 2006-10-10
US8637555B2 (en) 2014-01-28
GEP20094801B (en) 2009-10-26
MA28171A1 (fr) 2006-09-01
KR20060073974A (ko) 2006-06-29
TW200530221A (en) 2005-09-16
AU2004287861A1 (en) 2005-05-19
PL1599469T3 (pl) 2006-10-31
JP2007509181A (ja) 2007-04-12
PE20050483A1 (es) 2005-08-25
ES2267077T3 (es) 2007-03-01
DE602004001134D1 (de) 2006-07-20
CN1867562A (zh) 2006-11-22
RS20060290A (sr) 2008-11-28
AU2004287861B2 (en) 2008-08-14
NZ546285A (en) 2010-04-30
HRP20060286T3 (en) 2007-03-31
ZA200606203B (en) 2007-04-25
EP1599469A1 (en) 2005-11-30
IL174042A0 (en) 2006-08-01
MY140410A (en) 2009-12-31
EP1683794A1 (en) 2006-07-26
IS2372B (is) 2008-06-15
EA011484B1 (ru) 2009-04-28
NO20062509L (no) 2006-06-26
DE602004001134T2 (de) 2007-04-19
KR100850591B1 (ko) 2008-08-05
CN1867562B (zh) 2011-07-13
HK1076468A1 (en) 2006-01-20
TNSN06150A1 (en) 2007-11-15
DK1599469T3 (da) 2006-10-09
TWI258478B (en) 2006-07-21
US20060217562A1 (en) 2006-09-28
CO5690551A2 (es) 2006-10-31
JP2010163448A (ja) 2010-07-29
ZA200603419B (en) 2006-10-25
EA200600879A1 (ru) 2006-10-27
UA86783C2 (ru) 2009-05-25
US20070072924A1 (en) 2007-03-29
EP1599469B1 (en) 2006-06-07
WO2005044816A1 (en) 2005-05-19
IS8481A (is) 2006-05-24
CA2539985A1 (en) 2005-05-19
SI1599469T1 (sl) 2006-10-31
MXPA06004556A (es) 2006-07-06
BRPI0415631A (pt) 2006-12-12
CR8270A (es) 2006-10-06
ATE328880T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
JP2010163448A (ja) トリアゾール誘導体およびその代謝関連障害の処置方法
US7241792B2 (en) Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
JP2007509181A5 (https=)
US20090291968A1 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
EP1701947B1 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
VON et al. DISORDERS THEREOF
HK1087411A (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
HK1076468B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CN101087765A (zh) 稠合吡唑衍生物和其在治疗代谢相关病症的方法中的用途
MX2007007578A (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091210

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100520

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100614

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees